References
- 1. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23: 479–90.
- 2. Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993; 318(1): 83-7.
- 3. Kuroiwa K, Li H, Tago K, Iwahana H, Yanagisawa K, Komatsu N,et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma. 2000; 19(2): 151-9.
- 4. Liu X, Hammel M, He Y, Tainer JA, Jeng US, Zhang L, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci USA. 2013; 110(37): 14918-23.
- 5. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A. 2007; 104: 18660–5.
- 6. Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. 2018; 281(1): 154-168.
- 7. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007; 179: 2551–5.
- 8. Andrade MV, Iwaki S, Ropert C, Gazzinelli RT, Cunha- Melo JR, Beaven MA. Amplification of cytokine production through synergistic activation of NFAT and AP- 1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol. 2011; 41(3): 760-72.
- 9. Dunne A, O’Neill LA. The interleukin-1 receptor/Tolllike receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003; 2003(171):re3.
- 10. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem. 2012; 287(9): 6941-8.
- 11. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010; 10(2): 103-10
- 12. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A. 2010; 107:18581–6.
- 13. Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M, et al. IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol. 2013; 190:4489–99
- 14. Fairlie-Clarke K, Barbour M, Wilson C, Hridi SU, Allan D, Jiang HR. Expression and Function of IL-33/ST2 Axis in the Central Nervous System Under Normal and Diseased Conditions. Front Immunol. 2018; 9:2596.
- 15. Gadani SP, Walsh JT, Smirnov I, Zheng J, Kipnis J. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron. 2015; 85:703–9.
- 16. Yang Y, Liu H, Zhang H, Ye Q, Wang J. ST2/IL-33- dependent microglial response limits acute ischemic brain injury. J Neurosci. 2017; 37:4692–704.
- 17. Fu AK, Hung KW, Yuen MY, Zhou X, Mak DS, Chan IC, et al. IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016; 113(19): E2705-13.
- 18. Wicher G, Wallenquist U, Lei Y, Enoksson M, Li X, Fuchs B, et al. Interleukin-33 promotes recruitment of microglia/macrophages in response to traumatic brain injury. J Neurotrauma. 2017; 34(22): 3173–82.
- 19. Cao K, Liao X, Lu J, Yao S, Wu F, Zhu X, et al. IL- 33/ST2 plays a critical role in endothelial cell activation and microglia-mediated neuroinflammation modulation. J Neuroinflammation. 2018; 15(1): 136.
- 20. Dohi E, Choi EY, Rose IVL, Murata AS, Chow S, Niwa M, et al. Behavioral Changes in Mice Lacking Interleukin- 33. eNeuro. 2017; 4(6).
- 21. Vainchtein ID, Chin G, Cho FS, Kelley KW, Miller JG, Chien EC, et al. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science. 2018; 359(6381): 1269-1273.
- 22. Carlock C, Wu J, Shim J, Moreno-Gonzalez I, Pitcher MR, Hicks J, et al. Interleukin33 deficiency causes tau abnormality and neurodegeneration with Alzheimer-like symptoms in aged mice. Transl Psychiatry. 2017; 7(7): e1164.
- 23. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues,lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012; 188(7): 3488-95.
- 24. Natarajan C, Yao SY, Sriram S. TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair. PLoS One. 2016; 11(3): e0152163.
- 25. Jiang HR, Milovanović M, Allan D, Niedbala W, Besnard AG, Fukada SY, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur J Immunol. 2012; 42(7): 1804-14.
- 26. Allan D, Fairlie-Clarke KJ, Elliott C, Schuh C, Barnett SC, Lassmann H, et al. Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system. Acta Neuropathol Commun. 2016; 4(1): 75.
- 27. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, Zaheer A. Glia maturation factor induces interleukin- 33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol. 2013; 8(3): 643-50.
- 28. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochem Biophys Res Commun. 2012; 425(3): 534-9.
- 29. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014; 14(7): 463-477.
- 30. Luterman JD, Haroutunian V, Yemul S, et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000; 57(8): 1153-1160.
- 31. Serrano-Pozo A, Mielke ML, Gómez-Isla T, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol. 2011; 179(3): 1373-1384.
- 32. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013; 126(4): 479-497.
- 33. Holmes C, Cotterell D. Role of infection in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs. 2009; 23(12): 993-1002.
- 34. Holmes C. Review: systemic inflammation and Alzheimer’s disease. Neuropathol Appl Neurobiol. 2013; 39(1): 51-68.
- 35. Su X, Federoff HJ. Immune responses in Parkinson’s disease: interplay between central and peripheral immune systems. Biomed Res Int. 2014; 2014:275178.
- 36. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007; 55(5): 453-462.
- 37. Erickson MA, Banks WA. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: multiplex quantification with path analysis. Brain Behav Immun. 2011; 25(8): 1637-1648.
- 38. Park SM, Choi MS, Sohn NW, Shin JW. Ginsenoside Rg3 attenuates microglia activation following systemic lipopolysaccharide treatment in mice. Biol Pharm Bull. 2012; 35(9): 1546-1552.
- 39. Biesmans S, Meert TF, Bouwknecht JA, et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm. 2013; 2013:271359.
- 40. Tremblay MÈ, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci. 2011; 31(45): 16064-16069.
- 41. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998; 12(12): 1063-1073.
- 42. Brown GC. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans. 2007; 35(Pt 5): 1119-1121.
- 43. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer’s disease. Mol Psychiatry. 2009; 14(11): 1004-16.
- 44. Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A. Alzheimer’s disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis. 2014; 40(2): 297-308.
- 45. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011; 1385:8–17.
- 46. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry. 2001; 50:743–749.
- 47. Italiani P, Puxeddu I, Napoletano S, et al. Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression?. J Neuroinflammation. 2018; 15(1): 342.
- 48. Richardson JA, Burns DK. Mouse models of Alzheimer’s disease: a quest for plaques and tangles. ILAR J. 2002; 43: 89–99.
- 49. Saresella M, Marventano I, Piancone F, et al. IL-33 and its decoy sST2 in patients with Alzheimer’s disease and mild cognitive impairment. J Neuroinflammation. 2020; 17(1): 174.
- 50. Liang CS, Su KP, Tsai CL, et al. The role of interleukin- 33 in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther. 2020; 12(1): 86.
- 51. Gotz J, Ittner LM. Animal models of Alzheimer’s disease and frontotemporal dementia. Rev Neurosci 2008; 9: 532–544
- 52. Obulesu M, Rao DM. DNA damage and impairment of DNA repair in Alzheimer’s disease. Int J Neurosci 2010; 120: 397–403.
- 53. Hou Y, Song H, Croteau DL, Akbari M, Bohr VA. Genome instability in Alzheimer disease. Mech Ageing Dev 2017; 161: 83–94.
- 54. Malpass K. Alzheimer disease: DNA damage provides novel and powerful biomarkers of Alzheimer disease. Nat Rev Neurol. 2012; 8: 178.
- 55. Inoue K, Rispoli J, Kaphzan H, Klann E, Chen EI, Kim J et al. Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegen. 2012; 7: 48.
- 56. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006; 12: 856–861.
- 57. Pennisi M, Crupi R, Di Paola R, et al. Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease. J Neurosci Res. 2017; 95(7): 1360-1372.
- 58. Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci. 2014; 8:315.
- 59. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008; 9(8): 857-865.
- 60. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013; 493(7434): 674-678.
- 61. Rubartelli A. DAMP-mediated activation of NLRP3- inflammasome in brain sterile inflammation: the fine line between healing and neurodegeneration. Front Immunol. 2014; 5:99.
- 62. Wu GF, Alvarez E. The immunopathophysiology of multiple sclerosis. Neurol Clin. 2011; 29(2): 257-278.
- 63. Wang K, Song F, Fernandez-Escobar A, Luo G, Wang JH, Sun Y. The Properties of Cytokines in Multiple Sclerosis: Pros and Cons. Am J Med Sci. 2018; 356(6): 552-560.
- 64. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6): 707-717.
- 65. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006; 60(1): 12-21.
- 66. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol. 2002; 20:101-123.
- 67. Kouchaki E, Tamtaji OR, Dadgostar E, Karami M, Nikoueinejad H, Akbari H. Correlation of Serum Levels of IL-33, IL-37, Soluble Form of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Circulatory Frequency of VEGFR2-expressing Cells with Multiple Sclerosis Severity. Iran J Allergy Asthma Immunol. 2017; 16(4): 329-337
- 68. Zhang F, Tossberg JT, Spurlock CF, Yao SY, Aune TM, Sriram S. Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis. Ann Clin Transl Neurol. 2014; 1(5): 307-318.
- 69. Alsahebfosoul F, Rahimmanesh I, Shajarian M, et al. Interleukin- 33 plasma levels in patients with relapsing-remitting multiple sclerosis [published correction appears in Biomol Concepts. 2017;]. Biomol Concepts. 2017; 8(1): 55-60.
- 70. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 2012; 142: 308–19.
- 71. Kanda T. Interleukin-33/suppression of tumorigenicity 2 system: can it be a future therapeutic target for neuroimmunological disorders? Clin Exp Neuroimmunol. 2013; 4: 255–6
- 72. Wang S, Ding L, Liu S-S, Wang C, Leng R-X, Chen GM, et al. IL-33: a potential therapeutic target in autoimmune diseases. J Investig Med. 2012; 60: 1151–6.
- 73. Li M, Li Y, Liu X, Gao X, Wang Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol. 2012; 247(1-2): 25-31.
- 74. Chen H, Sun Y, Lai L, et al. Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice. Neuroscience. 2015; 308:157-168.
- 75. Xiao Y, Lai L, Chen H, et al. Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells. Mol Immunol. 2018; 101:550-563.
- 76. Barbour M, Wood R, Hridi SU, et al. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels. J Neuroimmunol. 2018; 318:87-96.
- 77. Zhao X, Zhang X, Lv Y, et al. Matrine downregulates IL-33/ST2 expression in the central nervous system of rats with experimental autoimmune encephalomyelitis. Immunol Lett. 2016; 178:97-104.
- 78. Jafarzadeh A, Mohammadi-Kordkhayli M, Ahangar- Parvin R, et al. Ginger extracts influence the expression of IL-27 and IL-33 in the central nervous system in experimental autoimmune encephalomyelitis and ameliorates the clinical symptoms of disease. J Neuroimmunol. 2014; 276(1-2):80-88.
- 79. Finlay CM, Stefanska AM, Walsh KP, et al. Helminth Products Protect against Autoimmunity via Innate Type 2 Cytokines IL-5 and IL-33, Which Promote Eosinophilia. J Immunol. 2016; 196(2):703-714.
- 80. Russi AE, Ebel ME, Yang Y, Brown MA. Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility. Proc Natl Acad Sci U S A. 2018; 115(7): E1520-E1529.